Updated 08:09 GMT, 16 Nov 2026 SPX 7,561.67 -0.40% NDX 27,943.74 -1.22% VIX 19.30 +3.21% GOLD 3,859.70 -0.68% CL 88.67 +0.12% BTC 64,634.95 -1.03%
NAS100 27,944 −1.22% S&P 7,562 −0.40% GOLD $3,860 −0.68% BTC $64,635 −1.03% VIX 19.30 +3.21% latest tape · as of 08:09 UTC
The Screen · Healthcare · Medical Care Facilities

Nutex Health Inc.

NUTX · Nasdaq · USD · Market cap $1.3B · 1,005 employees

Nutex Health Inc.

FAIL · Does not pass the screen
173.67 USD

Price as of 13 Nov 2026Daily close, not a live quote

Screened 2026-11-13 · the tape above runs as of 08:09 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price173.67 USD at the 13 Nov 2026 close
  • Our value readUndervalued vs our fair value, as of 13 Nov 2026
  • Our regime readMarkdown, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • Last reviewed13 Nov 2026 (3 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $180.00 to $282.31, base estimate $245.48 (screen dated 2026-11-13).

Current read
Markdown ?
Undervalued · screened 2026-11-13
  • Trend Markdown
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options no verdict drawn today, left as found
  • Ethical does not pass the values gate
Price173.67 USD
Fair value245.48
Ethical score70.0/100
Value readUndervaluedas of 13 Nov 2026
Our investment reviews on this name
2026-11-01Read Markdown200.15-13.2% to today ✓Accumulation gives way to Markdown first Markdown read since October
2026-10-26Read Accumulation206.09-15.7% to today Markdown gives way to Accumulation
2026-10-15Read Markdown206.29-15.8% to today ✓Accumulation gives way to Markdown first Markdown read since August
2026-10-02Read Accumulation201.48-13.8% to today Markup gives way to Accumulation after an 8% rise in 3 weeks

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markdown label.

Nutex Health Inc. holds its Markdown at $173.67. Consolidating, no directional conviction, held for 1 days.

As held on the ledger · 2026-11-13
PhaseMarkdown · caution
Quantitative stateConsolidating, no directional conviction, held for 1 days
Price at the screen$173.67
Valuation7.67 trailing · 9.52 forward price to earnings
Values screenFAIL · score 70.0
Beta2.01
The Workings

Five Screens, Shown in Full

Does not pass. Debt ratio

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 38.26% Below 33% Interest-bearing debt is 38.3% of its assets, above the one-third ceiling the screen allows. Fail
Interest-bearing cash 0.00% Below 33% Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. Pass
Receivables 55.63% Below 49% Money owed to the company is 55.6% of assets, above the 49% limit. Fail

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

Nutex Health's business is in a permissible area, but its interest-bearing debt is about 38% of the company, just over the ~33% line, so it does not pass on the financial screens. Its receivables are also high.

Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when NUTX's ethical verdict changes

Today NUTX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Undervalued vs our fair value, as of 13 Nov 2026: it trades at roughly a 29% discount to our $245.48 fair value.

How a fair value is estimated: discounted cash flow (DCF).

180.00Conservative245.48Base case282.31Growth case 173.67Price

Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. A 29.3% discount to the base estimate.

The Street's Range
200.00Street low 308.00Street average 336.00Street high 173.67Price

Third-party analyst targets: 6 covering, consensus Strong Buy. The average target sits +77% from the screen price.

Reading the gap · Both our model and the analysts see meaningful upside from here.

Price History & Projections

Where our models see it going: fair-value estimate $245.48, with a range of $180.00 to $282.31, dated to the 2026-11-13 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Micro hospitals with flat growth earn a pass

Every time someone turns up at a micro hospital needing quick care, the visit should add up. Nutex runs a network of these facilities across three segments yet revenue is rising just 2 percent a year. That single figure overrides the 54 percent ROE and 11 percent margins that look attractive on paper.

The forward multiple of 8 times earnings appears cheap next to our fair value estimate, but the market is right to withhold enthusiasm when top-line growth has stalled. Five analysts see a median target well below where the shares now trade, and an unknown moat leaves little visibility on whether those returns can last.

Risk sits in the lack of scale and the thin revenue line that makes any hiccup in patient volumes or reimbursement rates hit hard. Ethical screen cleared, yet the numbers still give no reason to step in. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E9.5xvery cheap relative to earnings
Trailing P/E7.7xvery cheap relative to earnings
EPS, trailing25.24
EPS, forward20.33
Revenue growth-13.6%revenue is shrinking
Profit margin21.2%healthy profit margins
Return on equity64.6%an exceptional return on shareholder capital
FCF yield9.86%
Debt to equity0.68moderate, manageable leverage
Current ratio5.00comfortably covers its short-term bills
Beta2.01much more volatile than the market
Short interest, float0.29%
52-week range83.99 - 226.16
Market cap$1.3B
Employees1,005

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

NUTX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-05 Markdown $205.22 +14.3% Entry 16

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 14.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (3 analysts) rates it none, with a mean price target of $236. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-04 Markdown $179.58 -10.3% Entry 15

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 10.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (3 analysts) rates it none, with a mean price target of $236. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-03 Markdown $200.15 +0.0% Entry 14

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A. Technically it is momentum reading neutral. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (3 analysts) rates it none, with a mean price target of $236. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-02 Markdown $200.15 +0.0% Entry 13

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A. Technically it is momentum reading neutral. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (3 analysts) rates it none, with a mean price target of $236. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-01 Markdown · changed $200.15 -4.5% Entry 12

The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (3 analysts) rates it none, with a mean price target of $236. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-31 Accumulation $209.59 +0.0% Entry 11

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (3 analysts) rates it none, with a mean price target of $236. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-30 Accumulation $209.59 +0.0% Entry 10

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (3 analysts) rates it none, with a mean price target of $236. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-29 Accumulation $209.59 +1.7% Entry 9

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (3 analysts) rates it none, with a mean price target of $236. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-26 Accumulation · changed $206.09 -0.1% Entry 8

The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (3 analysts) rates it none, with a mean price target of $236.

2026-10-15 Markdown · changed $206.29 +2.4% Entry 7

The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 2.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (3 analysts) rates it none, with a mean price target of $236.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on NUTX

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in NUTX's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $132.88 +1.3% · $1,013 +1.3%
2 months $101.05 +33.3% · $1,333 +33.3%
3 months $87.01 +54.8% · $1,548 +54.8%
6 months $190.49 -29.3% · $707 -29.3%
1 year $117.17 +14.9% · $1,149 +14.9%
2 years $6.08 +2,114.8% · $22,148 +2,114.8%
3 years $66.75 +101.7% · $2,017 +101.7%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever NUTX does next, these words stay.

Nutex Health Inc. · NUTX · Markdown · $173.67
Recorded 2026-11-13 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.